Breaking News

Astellas Invests $50M in Poseida Therapeutics

Comprises the purchase of shares for $25 million and an additional $25 million one-time payment for certain strategic rights.

Poseida Therapeutics, Inc., a clinical-stage cell and gene therapy company advancing a new class of treatments for cancer and rare diseases, reported a $50 million strategic investment by Astellas Pharma US, Inc. The investment is comprised of the purchase of shares of common stock for $25 million and an additional $25 million one-time payment for certain strategic rights. Mark Gergen, Poseida’s CEO said, “We are excited to announce a strategic investment by Astellas, a premier global p...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters